Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Corbus begins dosing in Phase II trial of Resunab to treat dermatomyositis
Resunab is a new synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells. The company noted that CB2 activation triggers
Resunab is a new synthetic oral drug that is a preferential agonist to the CB2 receptor expressed on activated immune cells. The company noted that CB2 activation triggers
FPA008 is an antibody that inhibits colony stimulating factor-1 receptor (CSF1R) and it targets macrophages and monocytes, which are activated or elevated in multiple disease settings. Five Prime
The 250mg once daily tablets are approved for NSCLC patients whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as
Prestalia, a first fixed-dose combination of perindopril arginine and amlodipine besylate, is now available by prescription for use in patients whose blood pressure is not adequately controlled on
In lupus, the body’s own immune system overreacts and attacks healthy organs, causing inflammation, pain, permanent organ damage or death. Adcetris is directed to CD30, which is expressed
The collaboration is based on combinations of Chimeric Antigen Receptor (CAR) T cells, developed at the laboratory of professor Hinrich Abken against multiple tumor-associated antigens, and apceth-developed engineered
hGH-CTP is a new long-acting recombinant human growth hormone analog being developed by OPKO to treat children with growth failure due to inadequate endogenous growth hormone secretion, and
Around 388 people with type 2 diabetes previously on diet and exercise were included in the trial, which evaluated the efficacy and safety of 0.5mg and 1.0mg semaglutide
Envarsus XR is an extended release formulation of tacrolimus designed for once-daily dosing, with flatter pharmacokinetics and greater bioavailability compared to twice-daily tacrolimus. The marketing approval is based
Imbruvica is approved in all 28 member states of the European Union (EU) to treat adults with WM who have received at least one prior therapy, or in